Onsera Health

Drug sourcing is one component of Onsera Health’s comprehensive cardiometabolic care platform, designed to address obesity and related conditions through a GLP-1/GIP-based treatment model supported by integrated clinical and behavioral care. Through Onsera Source, the platform provides flexible, cost-optimized access to medications—including strategic partnerships with Eli Lilly and Novo Nordisk—via direct manufacturer contracting, HRA-based models, and streamlined PBM pathways, ensuring affordability without sacrificing clinical quality.

As part of the broader care model, medication is paired with personalized clinical oversight, coaching, and nutrition support to drive sustained outcomes rather than short-term use. Onsera’s intelligence layer ensures the right medication is matched to the right participant, improving adherence, reducing misuse, and maximizing both clinical impact and cost efficiency.

Onsera partners with self-insured employers and health plans to deliver coordinated, end-to-end care that lowers pharmacy spend while improving overall population health and long-term cost outcomes.